Related Experiment Video
Updated: Oct 16, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Current approaches and future strategies for pancreatic carcinoma
1University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA.
Abstract:
Pancreatic cancer is a lethal disease characterized by local invasion and early dissemination. It is resistant to conventional surgical, radiotherapeutic, and chemotherapeutic modalities. These interventions have had minimal impact on overall survival with very few patients enjoying long term survival. Over the past few years, 2'difluoro-2'deoxycytidine (gemcitabine) has demonstrated modest activity in this disease and investigations are proceeding to expand its role in combination with radiotherapy and other chemotherapeutic agents. In addition, the identification of the molecular defects underlying this disease has suggested molecular targets for the design of rational systemic therapy. These targets include matrix metalloproteinases, K-ras, HER2/neu, p53, and the epidermal growth factor receptor. Current and future clinical trials designed to improve the survival of patients with pancreatic cancer will be discussed.
Insights
Pancreatic cancer is a deadly disease with poor survival rates. New treatments, including gemcitabine and targeted therapies, show promise for improving patient outcomes.
Area of Science:
- Oncology
- Gastroenterology
- Medical Research
Background:
- Pancreatic cancer is a highly lethal malignancy known for local invasion and early metastasis.
- Conventional treatments like surgery, radiation, and chemotherapy offer limited efficacy, resulting in poor long-term survival.
- The drug gemcitabine has shown some activity, prompting further research into its combination with other therapies.
Purpose of the Study:
- To review the current treatment landscape for pancreatic cancer.
- To discuss the role of gemcitabine in pancreatic cancer therapy.
- To explore emerging molecular targets and future clinical trial strategies for improving patient survival.
Main Methods:
- Literature review of pancreatic cancer treatment modalities.
- Analysis of gemcitabine's efficacy in clinical studies.
- Discussion of molecular targets identified in pancreatic cancer research.
- Overview of ongoing and planned clinical trials.
Main Results:
- Pancreatic cancer remains resistant to traditional therapies, with minimal impact on overall survival.
- Gemcitabine demonstrates modest activity, suggesting potential in combination regimens.
- Identification of molecular targets (e.g., MMPs, K-ras, HER2/neu, p53, EGFR) offers avenues for rational drug design.
Conclusions:
- Improving survival in pancreatic cancer requires novel therapeutic approaches beyond conventional methods.
- Combination therapies involving gemcitabine and targeted molecular agents represent a promising direction.
- Future clinical trials focusing on these new strategies are crucial for advancing patient care and outcomes.
